View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	FLGT
Entity Registrant Name	Fulgent Genetics, Inc.
Entity Central Index Key	0001674930
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,421,792
Entity File Number	001-37894
Entity Tax Identification Number	812621304
Entity Address, Address Line One	4978 Santa Anita Avenue, Suite 205
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 9,165	$ 6,736
Marketable securities	17,820	24,298
Trade accounts receivable, net of allowance for doubtful accounts of $585 and $590, as of June 30, 2019 and December 31, 2018, respectively	5,543	5,948
Other current assets	2,267	2,561
Total current assets	34,795	39,543
Marketable securities, long-term	11,697	6,386
Equity method investments	1,084	1,512
Fixed assets, net	5,937	6,446
Operating lease right-of-use asset	2,756
Other long-term assets	167	17
Total assets	56,436	53,904
Current liabilities
Accounts payable	1,175	1,313
Accrued liabilities	1,333	1,425
Operating lease liabilities, short-term	401
Total current liabilities	2,909	2,738
Operating lease liabilities, long-term	2,385
Other long-term liabilities		14
Total liabilities	5,294	2,752
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 18,393 and 18,172 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	2	2
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2019 and December 31, 2018
Additional paid-in capital	115,532	114,203
Accumulated other comprehensive income (loss)	203	(35)
Accumulated deficit	(64,595)	(63,018)
Total stockholders’ equity	51,142	51,152
Total liabilities and stockholders’ equity	$ 56,436	$ 53,904

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 585	$ 590
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	18,393,000	18,172,000
Common stock, shares outstanding	18,393,000	18,172,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Cost of revenue	3,620	2,544	6,588	5,316
Gross profit	4,804	2,856	7,206	4,737
Operating expenses:
Research and development	1,574	1,212	2,998	2,670
Selling and marketing	1,304	1,279	2,576	2,409
General and administrative	1,631	1,366	3,160	2,853
Total operating expenses	4,509	3,857	8,734	7,932
Operating income (loss)	295	(1,001)	(1,528)	(3,195)
Interest and other income, net	192	98	399	193
Income (loss) before income taxes and equity loss in investee	487	(903)	(1,129)	(3,002)
Provision for (benefit from) income taxes	7	(100)	20	(534)
Income (loss) before equity loss in investee	480	(803)	(1,149)	(2,468)
Equity loss in investee	(149)	(246)	(428)	(491)
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Net income (loss) per common share:
Basic	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Diluted	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Weighted-average common shares:
Basic	18,343	17,919	18,286	17,891
Diluted	19,021	17,919	18,286	17,891

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	(14)	(43)	1	(21)
Net unrealized gain (loss) on marketable securities, net of tax	122	48	237	(17)
Comprehensive income (loss)	$ 439	$ (1,044)	$ (1,339)	$ (2,997)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Stockholders' Equity	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ 54,178	$ 2	$ 111,884	$ (44)	$ (57,664)
Beginning Balance, Shares at Dec. 31, 2017		17,847,000
Equity-based compensation	1,118		1,118
Exercise of common stock options	9		9
Exercise of common stock options, Shares		23,000
Restricted stock awards, Shares		93,000
Cumulative effect of accounting change	327				327
Cumulative tax effect of accounting change	(74)				(74)
Other comprehensive gain (loss), net	(38)			(38)
Net income (loss)	(2,959)				(2,959)
Ending Balance at Jun. 30, 2018	52,561	$ 2	113,011	(82)	(60,370)
Ending Balance, Shares at Jun. 30, 2018		17,963,000
Beginning Balance at Mar. 31, 2018	53,025	$ 2	112,431	(87)	(59,321)
Beginning Balance, Shares at Mar. 31, 2018		17,876,000
Equity-based compensation	573		573
Exercise of common stock options	7		7
Exercise of common stock options, Shares		18,000
Restricted stock awards, Shares		69,000
Other comprehensive gain (loss), net	5			5
Net income (loss)	(1,049)				(1,049)
Ending Balance at Jun. 30, 2018	52,561	$ 2	113,011	(82)	(60,370)
Ending Balance, Shares at Jun. 30, 2018		17,963,000
Beginning Balance at Dec. 31, 2018	$ 51,152	$ 2	114,203	(35)	(63,018)
Beginning Balance, Shares at Dec. 31, 2018	18,172,000	18,172,000
Equity-based compensation	$ 1,320		1,320
Exercise of common stock options	9		9
Exercise of common stock options, Shares		24,000
Restricted stock awards, Shares		197,000
Other comprehensive gain (loss), net	238			238
Net income (loss)	(1,577)				(1,577)
Ending Balance at Jun. 30, 2019	$ 51,142	$ 2	115,532	203	(64,595)
Ending Balance, Shares at Jun. 30, 2019	18,393,000	18,393,000
Beginning Balance at Mar. 31, 2019	$ 49,961	$ 2	114,790	95	(64,926)
Beginning Balance, Shares at Mar. 31, 2019		18,286,000
Equity-based compensation	737		737
Exercise of common stock options	5		5
Exercise of common stock options, Shares		15,000
Restricted stock awards, Shares		92,000
Other comprehensive gain (loss), net	108			108
Net income (loss)	331				331
Ending Balance at Jun. 30, 2019	$ 51,142	$ 2	$ 115,532	$ 203	$ (64,595)
Ending Balance, Shares at Jun. 30, 2019	18,393,000	18,393,000

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities:
Net loss	$ (1,577,000)	$ (2,959,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity-based compensation	1,320,000	1,118,000
Depreciation	1,046,000	1,078,000
Noncash lease expense	201,000
Loss on disposal of fixed asset	11,000	55,000
Amortization of premium of marketable securities	44,000	160,000
Provision for bad debt		230,000
Deferred taxes		(535,000)
Equity loss in investee	428,000	491,000
Other	38,000	38,000
Changes in operating assets and liabilities:
Accounts receivable	368,000	(990,000)
Other current and long-term assets	183,000	22,000
Accounts payable	(124,000)	(1,344,000)
Accrued liabilities	(20,000)	1,288,000
Operating lease liabilities	(188,000)
Net cash provided by (used in) operations	1,730,000	(1,348,000)
Cash flow from investing activities:
Purchases of fixed assets	(633,000)	(1,152,000)
Purchase of marketable securities	(10,178,000)	(11,470,000)
Maturities of marketable securities	11,500,000	11,656,000
Purchase of equipment contributed to Equity Method Investee		(510,000)
Net cash (used in) provided by investing activities	689,000	(1,476,000)
Cash flow from financing activities:
Proceeds from exercise of stock options	9,000	9,000
Net cash provided by financing activities	9,000	9,000
Effect of exchange rate changes on cash and cash equivalents	1,000	(21,000)
Net decrease in cash	2,429,000	(2,836,000)
Cash balance at beginning of period	6,736,000	6,490,000
Cash balance at end of period	9,165,000	3,654,000
Supplemental disclosures of cash flow information:
Income taxes paid	20,000	1,000
Supplemental disclosures of non-cash investing and financing activities:
Fixed assets included in accounts payable	$ 5,000	$ 1,011,000

Overview and Basis of Presentation

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a growing technology company offering comprehensive genetic testing and providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows us to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with our technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique genetic testing needs.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2018, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2019 (the “2018 Annual Report”), and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying condensed consolidated balance sheet as of December 31, 2018 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2018 Annual Report, including the notes thereto.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2018 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. Actual results could differ from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) equity method investments.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying condensed consolidated statements of stockholders’ equity. Gains and losses from these translations were not significant in the first six months of 2019 and 2018. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements were not significant in the first six months of 2019 and 2018.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use (“ROU”) assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s condensed consolidated balance sheets.

ROU lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since our leases do not provide an implicit rate. The ROU lease asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. In the three months ended June 30, 2019, after aggregating customers that are under common control or are affiliates, two customers contributed 32% and 15%, respectively, of our revenue for the period. In the six months ended June 30, 2019, after aggregating customers that are under common control or are affiliates, two customers contributed 27% and 10%, respectively, of our revenue for the period. In the three and six months ended June 30, 2018, after aggregating customers that are under common control or are affiliates, one customer contributed 13% of our revenue.

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types, Clinical Institutional, Patients who pay directly or Clinical Insurance, as we believe this best depicts how the nature, amount, timing, and uncertainty of our revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the in the first six months of 2019 and 2018.

	Three months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	8,160	$	4,782
Patient		143		156
Insurance		121		462
Total Revenue	$	8,424	$	5,400

	Six months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	13,279	$	9,247
Patient		245		272
Insurance		270		534
Total Revenue	$	13,794	$	10,053

Contract Balances

Receivables from contracts with customers - As of June 30, 2019 and December 31, 2018, receivables from contracts with customers were approximately $5.5 million and $5.9 million, respectively, and are included within Trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities - As of June 30, 2019 and December 31, 2018, contract assets and liabilities from contracts with customers were not material.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with Genetic Testing Services that extend beyond one year.

Recent Accounting Pronouncements Adopted

ASU No. 2016-02

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC 840, Leases. The FASB has issued subsequent amendments to improve and clarify the implementation guidance of Topic 842. The new standard requires an entity to recognize leases on the balance sheet and to disclose key information about the entity's leasing arrangements. The Company adopted this standard as of January 1, 2019 using the modified retrospective transition approach, including certain practical expedients, for all leases existing as of January 1, 2019, the effective and initial application date. Prior period financial statements were not recast under the new guidance. The Company elected to apply practical expedients, to not separate non-lease components from lease components, and to not reassess lease classification, treatment of initial direct costs, or whether an existing or expired contract contains a lease. The Company also elected to use the short-term exemption for all class assets. The adoption of the new standard resulted in recognition of operating lease liabilities of approximately $3.0 million with corresponding right-of-use assets of approximately the same amount. There was no impact to retained earnings upon adoption. This standard had a material impact on the condensed consolidated balance sheets and did not have a material impact on the Company’s condensed consolidated statements of operations and consolidated statements of cash flows.

See Note 9, Leases, for further information.

ASU No. 2017-08

In March 2017, the FASB issued ASU No. 2017-08, Receivables–Nonrefundable Fees and Other Costs (Subtopic 310-20). Under the ASU, entities must amortize to the earliest call date the premium on certain purchased callable debt securities. The ASU does not require any accounting change for debt securities held at a discount. The guidance calls for a modified retrospective transition approach under which a cumulative-effect adjustment will be made to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company’s marketable security portfolio amortizes to the earliest call date the premium on certain purchased callable debt securities. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements or disclosure.

ASU No. 2018-02

In February 2018, the FASB issued ASU 2018-02 Income Statement - Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which gives entities the option to reclassify to retained earnings the tax effects resulting from the Tax Act related to items in Additional Other Comprehensive Income (AOCI) that the FASB refers to as having been “stranded” in AOCI. The guidance is effective for annual and interim periods beginning after December 15, 2018, and is applicable to the Company in fiscal year 2019; however, early adoption is permitted. The Company adopted ASU 2018-02 as of January 1, 2019 and elected not to reclassify the income tax effect of the Tax Act from AOCI to retained earnings. The adoption of ASU 2018-02 resulted in no impact to the Company's financial statements.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Condensed Consolidated Financial Statements.

ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU No. 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief. This update adds optional transition relief for entities to elect the fair value option for certain financial assets previously measured at amortized cost basis to increase comparability of similar financial assets. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods. Early adoption is permitted. The Company has not yet evaluated the effect this ASU will have on its consolidated financial statements and related disclosures.

ASU No. 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations.

Marketable Securities

6 Months Ended

Jun. 30, 2019

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

	June 30, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	3,722			—		—		$	3,722
United States Treasury		999			—		—			999
U.S. government agency securities		797			1		—			798
Corporate debt securities		16,014			22		(13	)		16,023
Less: Cash equivalents		(3,722	)		—		—			(3,722	)
Total short-term marketable securities		17,810			23		(13	)		17,820
Corporate debt securities		11,561			136		—			11,697
Total long-term marketable securities		11,561			136		—			11,697
Total marketable securities	$	29,371		$	159	$	(13	)	$	29,517

	December 31, 2018
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	2,692		$	—	$	—		$	2,692
United States Treasury		990			—		—			990
U.S. government agency securities		790			—		—			790
Corporate debt securities		22,613			1		(96	)		22,518
Less: Cash equivalents		(2,692	)		—		—			(2,692	)
Total short-term marketable securities		24,393			1		(96	)		24,298
Corporate debt securities		6,383			11		(8	)		6,386
Total long-term marketable securities		6,383			11		(8	)		6,386
Total marketable securities	$	30,776		$	12	$	(104	)	$	30,684

Management determined that the gross unrealized losses of $13,000 on the Company’s marketable securities as of June 30, 2019 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $104,000 as of December 31, 2018. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of June 30, 2019.

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	June 30, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	27,720	$	—	$	27,720	$	—
United States Treasury		999		—		999		—
U.S. government agency securities		798		—		798		—
Money market accounts		3,722		3,722		—		—
Total marketable securities and cash equivalents	$	33,239	$	3,722	$	29,517	$	—

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	28,904	$	—	$	28,904	$	—
United States Treasury		990		—		990		—
U.S. government agency securities		790		—		790		—
Money market accounts		2,692		2,692		—		—
Total marketable securities and cash equivalents	$	33,376	$	2,692	$	30,684	$	—

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of United States Treasury, U.S. government agency securities, and corporate debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of June 30, 2019, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the first six months of 2019.

Gross unrealized gains or losses for cash equivalents and marketable securities as of June 30, 2019 were not material. As of June 30, 2019, unrealized losses for securities in an unrealized loss position for more than 12 months were $13,000. During the three months ended June 30, 2019, the Company did not recognize other-than-temporary impairment losses related to its marketable securities.

Fixed Assets

6 Months Ended

Jun. 30, 2019

Property Plant And Equipment [Abstract]

Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

		June 30,			December 31,
	Useful Lives	2019			2018
		(in thousands)
Computer hardware	3 Years	$	1,687		$	1,579
Computer software	3 Years		530			495
Medical lab equipment	5 Years		8,136			8,136
Furniture and fixtures	5 Years		234			233
Leasehold improvements	Shorter of lease term or estimated useful life		802			802
Assets not yet placed in service			1,485			1,087
Total			12,874			12,332
Less: Accumulated depreciation			(6,937	)		(5,886	)
Property and equipment, net		$	5,937		$	6,446

Depreciation expense on fixed assets totaled $511,000 and $562,000 for the three months and $1.0 million and $1.1 million for the six months ended June 30, 2019 and 2018, respectively.

Significant Balance Sheet Accounts

6 Months Ended

Jun. 30, 2019

Balance Sheet Related Disclosures [Abstract]

Significant Balance Sheet Accounts

Note 6. Significant Balance Sheet Accounts

Other current assets consisted of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Reagents	$	405	$	314
Prepaid expenses		1,024		706
Prepaid income taxes		609		1,251
Marketable securities interest receivable		196		220
Other receivable		33		70
Total	$	2,267	$	2,561

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographic Information

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. All long-lived assets were located in the United States during the first half of 2019 and 2018. Revenue by region was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Revenue:
United States	$	6,686	$	3,299	$	10,300	$	5,826
Foreign:
Canada		516		1,070		1,054		2,040
Other Countries		1,222		1,031		2,440		2,187
Total	$	8,424	$	5,400	$	13,794	$	10,053

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Operating Leases

See Note 9, Leases, for further information.

FF Gene Biotech

See Note 14 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 14).

Purchase Obligations

As of June 30, 2019, the Company had non-cancelable purchase obligations of $5.8 million for reagents, of which, $2.1 million is payable within twelve months, and $3.7 million is payable within the next twenty-four months.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

Note 9. Leases

The Company has various non-cancelable operating leases with varying terms through August 2023 primarily for office space. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. The Company does not have any finance leases or leases with variable lease payments.

The determination of whether an arrangement contains a lease is made at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset.

The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health. Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative functions.

Rent expense was approximately $133,000 and $119,000 for the three months ended and $266,000 and $228,000 for the six months ended June 30, 2019 and 2018, respectively.

The Company adopted new accounting standard ASC 842, Leases, on January 1, 2019. Upon adoption, the Company recorded ROU assets of $3.0 million and short-term and long-term lease liabilities of $384,000 and $2.6 million, respectively. The difference between the ROU asset and liability is due to the existing balance of deferred rent at the date of adoption. There was no impact to retained earnings upon adoption.

Our incremental borrowing rate was used to determine the present value of lease payments since our leases do not provide an implicit rate. The Company determined its incremental borrowing rate based on inquiries with our bank. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. Our leases do not contain variable lease payments. The Company does not have any short-term leases and thus has excluded short-term costs from the table below. The Company did not enter into any new leases during the six months ended June 30, 2019.

The following was operating lease expense:

Three months ended

June 30, 2019

Six months ended

June 30, 2019

Operating lease cost

146

292

Supplemental cash flow information related to leases was the following:

Three months ended

June 30, 2019

Six months ended

June 30, 2019

Cash paid for amounts included in the measurement of lease liabilities

116

278

Operating cash flows from operating leases

101

201

Supplemental balance sheet information related to leases was the following:

	June 30, 2019
Weighted average remaining lease term - operating leases	6.1 years
Weighted average discount rate - operating leases		6.25	%

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2019 (remaining 6 months)	$	281
2020		559
2021		550
2022		558
2023		567
2024		330
Thereafter		532
Total lease payments		3,377
Less imputed interest		(591	)
Total	$	2,786

Future minimum payments under non-cancelable operating leases as of December 31, 2018 are as follows:

	Amounts
	(in thousands)
Year ending December 31,
2019	$	560
2020		559
2021		550
2022		558
2023		567
Thereafter		862
Total minimum lease payments	$	3,656

Equity-Based Compensation

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying condensed consolidated statements of operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Cost of revenue	$	167	$	151	$	309	$	275
Research and development		233		171		411		303
Selling and marketing		186		113		311		221
General and administrative		151		138		289		319
Total	$	737	$	573	$	1,320	$	1,118

Income Taxes

6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate for the full fiscal year ending December 31, 2019, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates, adjusted for discrete items recognized during the period. Certain significant or unusual items are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.

The Company’s effective tax rate was 1% and -2% for the three and six months ended June 30, 2019, respectively, compared with 11% and 18% for the three and six months ended June 30, 2018, respectively. The change in effective tax rate for the three months and six months ended June 30, 2019, was primarily attributable to the full valuation allowance.

Loss Per Share

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Loss per Share

Note 12. Loss per Share

The following table presents the calculation of basic and diluted loss per share for the three and six months ended June 30, 2019 and 2018:

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019			2018
	(in thousands, except per share data)
Net income (loss)	$	331	$	(1,049	)	$	(1,577	)	$	(2,959	)
Weighted-average common shares—outstanding, basic		18,343		17,919			18,286			17,891
Weighted-average common shares—outstanding, diluted		19,021		17,919			18,286			17,891
Net income (loss) per common share, basic	$	0.02	$	(0.06	)	$	(0.09	)	$	(0.17	)
Net income (loss) per common share, diluted	$	0.02	$	(0.06	)	$	(0.09	)	$	(0.17	)

The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)
Options		19		436		387		433
RSUs		358		1,055		1,093		961

The anti-dilutive shares described above were calculated using the treasury stock method. During the three months ended June 30, 2018 and the first six months ended June 30, 2019 and 2018, the Company had outstanding stock options and RSUs that were excluded from the weighted-average share calculation due to the Company’s net loss position.

Related Party

6 Months Ended

Jun. 30, 2019

Related Party

Note 13. Related Party

Dr. Yun Yen, who is a member of the Company’s Board of Directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation (the “Foundation”) and served as the President for the Taipei Medical University (the “University”), from August 1, 2011 through July 31, 2016.

From time to time, the Company performs research testing services, on an arms-length basis, for the Foundation. The Company recognized $2,000 in revenue during the three and six months ended June 30, 2019 and zero for the three and six months ended June 30, 2018, as consideration for such services. Additionally, the Company subleased certain of its headquarters facilities to the Foundation. The Company recognized $8,000 and zero for the three months and $16,000 and $8,000 for the six months ended June 30, 2019 and 2018, respectively, as consideration for such sublease. As of June 30, 2019, and December 31, 2018, $2,000 and zero, respectively, was owed to the Company by the Foundation in connection with these relationships.

From time to time, the Company performs genetic sequencing services, on an arms-length basis, for the University. The Company recognized $9,000 and $7,000 for the three months ended and $22,000 and $16,000 for the six months ended June 30, 2019 and 2018, respectively, as consideration for such services. As of June 30, 2019, and December 31, 2018, $18,000 and $51,000, respectively, was owed to the Company by the University in connection with this relationship.

As more fully described in Note 14, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement (the “JV Agreement”) with Xilong Scientific Co., Ltd. (“Xilong Scientific”) and Fuzhou Jinqiang Investment Partnership (LP) (“FJIP”) to form a joint venture under the laws of the People’s Republic of China (“PRC”) called Fujian Fujun Gene Biotech Co., Ltd. (“FF Gene Biotech”). Xilong Scientific is an affiliate of Xi Long USA, Inc., a large stockholder of the Company that, as of June 30, 2019, owned 11% of the outstanding shares of the Company’s common stock, and FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP.

Fulgent Pharma utilizes space in the facility at which our laboratory and corporate headquarters are located. Since the completion of the Pharma Split-Off, Fulgent Pharma reimburses us for the portion of the rent we pay that is attributable to the space it uses, which amounts are not significant. As of June 30, 2019, and December 31, 2018, $29,000 and $22,000, respectively, was due from Fulgent Pharma as a result of this arrangement, which is recorded in Other receivable in Other current assets in the accompanying condensed consolidated balance sheets.

Equity Method Investments

6 Months Ended

Jun. 30, 2019

Equity Method Investments And Joint Ventures [Abstract]

Equity Method Investments

Note 14. Equity Method Investments

In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi (“RMB”) over a five-year period for a 30% ownership interest in FF Gene Biotech, previously three-year per original agreement. Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a five-year period for a 51% ownership interest in the FF Gene Biotech, previously three-year per original agreement. FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a ten-year period for a 19% ownership interest in FF Gene Biotech, previously five-year per original agreement. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of June 30, 2019, 40.3 million RMB (or approximately $5.9 million U.S. dollars) remains to be contributed to the investee under the terms of the JV agreement. To date, the Company has purchased and contributed equipment with an aggregate fair value of $3.0 million pursuant to its contribution commitment under the JV Agreement. The Company accounted for this contribution in accordance with ASC 845, Nonmonetary Transactions, and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone does not have the power to direct the most significant activities of FF Gene Biotech and therefore is not the primary beneficiary of the entity. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech in the three months ended June 30, 2019 in the accompanying condensed consolidated statements of operations, and recorded its contribution to date, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying condensed consolidated balance sheet as of June 30, 2019.

The Company entered into a license agreement with FF Gene Biotech, pursuant to which it granted FF Gene Biotech a license to use certain of the Company’s clinical molecular diagnostic gene detection technology and related software and proprietary reference library of genetic information, along with any improvements on this technology that they may develop during the term of the license agreement. Under the license agreement, FF Gene Biotech will pay to the Company, on a quarterly basis, certain royalties based on the revenues of FF Gene Biotech. The license agreement expired on December 31, 2018. The Company earned $17,000 and $35,000 for royalties under the license agreement for the three and six months ended June 30, 2018, respectively.

In November 2017, FF Gene Biotech invested and formed a majority-owned subsidiary that focuses on sales and marketing for FF Gene Biotech.

Equity method investments as of June 30, 2019 and December 31, 2018 consisted of the following:

	June 30, 2019					December 31, 2018
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	1,084		30	%	$	1,512		30	%
Total equity method investments	$	1,084		30	%	$	1,512		30	%

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	June 30,		December 31,
	2019		2018
Consolidated Balance Sheets Data:	(in thousands)
Current Assets	$	2,367	$	1,916
Non-Current Assets		3,892		4,068
Current Liabilities		4,318		2,415
Non-Current Liabilities		—		—
Minority Interest		207		—
Shareholders' Equity		1,734		3,569

	Six Months Ended June 30
	2019			2018
Consolidated Statements of Operations Data:	(in thousands)
Net Sales	$	1,131		$	349
Gross Profit		579			(1	)
Net Loss		(1,423	)		(1,637	)
Share of loss from investments accounted for using the equity method (1)		(428	)		(491	)

(1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Use of Estimates

Foreign Currency Translation and Foreign Currency Transactions

Leases

Concentration of Customers

Revenue from Contracts with Customers

Disaggregation of Revenue

	Three months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	8,160	$	4,782
Patient		143		156
Insurance		121		462
Total Revenue	$	8,424	$	5,400

	Six months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	13,279	$	9,247
Patient		245		272
Insurance		270		534
Total Revenue	$	13,794	$	10,053

Contract Balances

Contracts assets and liabilities - As of June 30, 2019 and December 31, 2018, contract assets and liabilities from contracts with customers were not material.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with Genetic Testing Services that extend beyond one year.

Recent Accounting Pronouncements Adopted and Recent Accounting Pronouncements

Recent Accounting Pronouncements Adopted

ASU No. 2016-02

See Note 9, Leases, for further information.

ASU No. 2017-08

ASU No. 2018-02

Recent Accounting Pronouncements

ASU No. 2016-13

ASU No. 2018-15

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Standards Update 2014-09

Summary of Revenue from Contracts with Customers by Payor Type

The following table summarizes revenue from contracts with customers by payor type for the in the first six months of 2019 and 2018.

	Three months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	8,160	$	4,782
Patient		143		156
Insurance		121		462
Total Revenue	$	8,424	$	5,400

	Six months ended June 30,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	13,279	$	9,247
Patient		245		272
Insurance		270		534
Total Revenue	$	13,794	$	10,053

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2019

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

	June 30, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	3,722			—		—		$	3,722
United States Treasury		999			—		—			999
U.S. government agency securities		797			1		—			798
Corporate debt securities		16,014			22		(13	)		16,023
Less: Cash equivalents		(3,722	)		—		—			(3,722	)
Total short-term marketable securities		17,810			23		(13	)		17,820
Corporate debt securities		11,561			136		—			11,697
Total long-term marketable securities		11,561			136		—			11,697
Total marketable securities	$	29,371		$	159	$	(13	)	$	29,517

	December 31, 2018
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	2,692		$	—	$	—		$	2,692
United States Treasury		990			—		—			990
U.S. government agency securities		790			—		—			790
Corporate debt securities		22,613			1		(96	)		22,518
Less: Cash equivalents		(2,692	)		—		—			(2,692	)
Total short-term marketable securities		24,393			1		(96	)		24,298
Corporate debt securities		6,383			11		(8	)		6,386
Total long-term marketable securities		6,383			11		(8	)		6,386
Total marketable securities	$	30,776		$	12	$	(104	)	$	30,684

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	June 30, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	27,720	$	—	$	27,720	$	—
United States Treasury		999		—		999		—
U.S. government agency securities		798		—		798		—
Money market accounts		3,722		3,722		—		—
Total marketable securities and cash equivalents	$	33,239	$	3,722	$	29,517	$	—

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	28,904	$	—	$	28,904	$	—
United States Treasury		990		—		990		—
U.S. government agency securities		790		—		790		—
Money market accounts		2,692		2,692		—		—
Total marketable securities and cash equivalents	$	33,376	$	2,692	$	30,684	$	—

Fixed Assets (Tables)

6 Months Ended

Jun. 30, 2019

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

		June 30,			December 31,
	Useful Lives	2019			2018
		(in thousands)
Computer hardware	3 Years	$	1,687		$	1,579
Computer software	3 Years		530			495
Medical lab equipment	5 Years		8,136			8,136
Furniture and fixtures	5 Years		234			233
Leasehold improvements	Shorter of lease term or estimated useful life		802			802
Assets not yet placed in service			1,485			1,087
Total			12,874			12,332
Less: Accumulated depreciation			(6,937	)		(5,886	)
Property and equipment, net		$	5,937		$	6,446

Significant Balance Sheet Accounts (Tables)

6 Months Ended

Jun. 30, 2019

Balance Sheet Related Disclosures [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Reagents	$	405	$	314
Prepaid expenses		1,024		706
Prepaid income taxes		609		1,251
Marketable securities interest receivable		196		220
Other receivable		33		70
Total	$	2,267	$	2,561

Reporting Segment and Geographic Information (Tables)

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Revenue:
United States	$	6,686	$	3,299	$	10,300	$	5,826
Foreign:
Canada		516		1,070		1,054		2,040
Other Countries		1,222		1,031		2,440		2,187
Total	$	8,424	$	5,400	$	13,794	$	10,053

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of Operating Lease Expense

The following was operating lease expense:

Three months ended

June 30, 2019

Six months ended

June 30, 2019

Operating lease cost

146

292

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was the following:

Three months ended

June 30, 2019

Six months ended

June 30, 2019

Cash paid for amounts included in the measurement of lease liabilities

116

278

Operating cash flows from operating leases

101

201

Schedule of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was the following:

	June 30, 2019
Weighted average remaining lease term - operating leases	6.1 years
Weighted average discount rate - operating leases		6.25	%

Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2019 (remaining 6 months)	$	281
2020		559
2021		550
2022		558
2023		567
2024		330
Thereafter		532
Total lease payments		3,377
Less imputed interest		(591	)
Total	$	2,786

Schedule of Future Minimum Payments for Noncancelable Operating Leases

Future minimum payments under non-cancelable operating leases as of December 31, 2018 are as follows:

	Amounts
	(in thousands)
Year ending December 31,
2019	$	560
2020		559
2021		550
2022		558
2023		567
Thereafter		862
Total minimum lease payments	$	3,656

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying condensed consolidated statements of operations as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Cost of revenue	$	167	$	151	$	309	$	275
Research and development		233		171		411		303
Selling and marketing		186		113		311		221
General and administrative		151		138		289		319
Total	$	737	$	573	$	1,320	$	1,118

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Reconciliation of the Basic and Diluted Loss Per Share Computations

The following table presents the calculation of basic and diluted loss per share for the three and six months ended June 30, 2019 and 2018:

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019			2018
	(in thousands, except per share data)
Net income (loss)	$	331	$	(1,049	)	$	(1,577	)	$	(2,959	)
Weighted-average common shares—outstanding, basic		18,343		17,919			18,286			17,891
Weighted-average common shares—outstanding, diluted		19,021		17,919			18,286			17,891
Net income (loss) per common share, basic	$	0.02	$	(0.06	)	$	(0.09	)	$	(0.17	)
Net income (loss) per common share, diluted	$	0.02	$	(0.06	)	$	(0.09	)	$	(0.17	)

Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share

The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
	(in thousands)
Options		19		436		387		433
RSUs		358		1,055		1,093		961

Equity Method Investments (Tables)

6 Months Ended

Jun. 30, 2019

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Equity Method Investments

Equity method investments as of June 30, 2019 and December 31, 2018 consisted of the following:

	June 30, 2019					December 31, 2018
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	1,084		30	%	$	1,512		30	%
Total equity method investments	$	1,084		30	%	$	1,512		30	%

Summary of Financial Information for Equity Method Investees

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	June 30,		December 31,
	2019		2018
Consolidated Balance Sheets Data:	(in thousands)
Current Assets	$	2,367	$	1,916
Non-Current Assets		3,892		4,068
Current Liabilities		4,318		2,415
Non-Current Liabilities		—		—
Minority Interest		207		—
Shareholders' Equity		1,734		3,569

	Six Months Ended June 30
	2019			2018
Consolidated Statements of Operations Data:	(in thousands)
Net Sales	$	1,131		$	349
Gross Profit		579			(1	)
Net Loss		(1,423	)		(1,637	)
Share of loss from investments accounted for using the equity method (1)		(428	)		(491	)

(1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019 USD ($) Customer	Jun. 30, 2018 Customer	Jun. 30, 2019 USD ($) Customer	Jun. 30, 2018 Customer	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Trade accounts receivable, net of allowance for doubtful accounts of $585 and $590, as of June 30, 2019 and December 31, 2018, respectively	$ 5,543		$ 5,543			$ 5,948
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations			true
Operating lease liabilities	2,786		$ 2,786		$ 3,000
Right-of-use assets	$ 2,756		$ 2,756		$ 3,000
Customer Concentration Risk \| Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	2	1	2	1
Customer Concentration Risk \| Revenue \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	32.00%	13.00%	27.00%	13.00%
Customer Concentration Risk \| Revenue \| Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	15.00%		10.00%

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Type of Revenue [Extensible List]	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember
Revenue from contracts with customers by payor type	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Accounting Standards Update 2014-09 \| Clinical Institutional Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	8,160	4,782	13,279	9,247
Accounting Standards Update 2014-09 \| Clinical Patient Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	143	156	245	272
Accounting Standards Update 2014-09 \| Clinical Insurance Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 121	$ 462	$ 270	$ 534

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 29,371	$ 30,776
Marketable securities, Unrealized Gains	159	12
Marketable securities, Unrealized Losses	(13)	(104)
Marketable securities, Aggregate Fair Value	29,517	30,684
Cash and cash equivalents	9,165	6,736	$ 3,654	$ 6,490
Less: cash equivalents	(3,722)	(2,692)
Short-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	17,810	24,393
Marketable securities, Unrealized Gains	23	1
Marketable securities, Unrealized Losses	(13)	(96)
Marketable securities, Aggregate Fair Value	17,820	24,298
Short-Term Marketable Securities \| Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	16,014	22,613
Marketable securities, Unrealized Gains	22	1
Marketable securities, Unrealized Losses	(13)	(96)
Marketable securities, Aggregate Fair Value	16,023	22,518
Short-Term Marketable Securities \| United States Treasury
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	999	990
Marketable securities, Aggregate Fair Value	999	990
Short-Term Marketable Securities \| U.S. Government Agency Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	797	790
Marketable securities, Unrealized Gains	1
Marketable securities, Aggregate Fair Value	798	790
Long-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	11,561	6,383
Marketable securities, Unrealized Gains	136	11
Marketable securities, Unrealized Losses		(8)
Marketable securities, Aggregate Fair Value	11,697	6,386
Long-Term Marketable Securities \| Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	11,561	6,383
Marketable securities, Unrealized Gains	136	11
Marketable securities, Unrealized Losses		(8)
Marketable securities, Aggregate Fair Value	11,697	6,386
Short Term Marketable Securities \| Money Market Accounts
Schedule of Available For Sale Securities [Line Items]
Cash and cash equivalents	3,722	2,692
Cash and cash equivalents fair value disclosure	$ 3,722	$ 2,692

Marketable Securities - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss	$ 13,000	$ 104,000

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 29,517	$ 30,684
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	33,239	33,376
Fair Value Measurements Recurring \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	3,722	2,692
Fair Value Measurements Recurring \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	29,517	30,684
Fair Value Measurements Recurring \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	0	0
Fair Value Measurements Recurring \| Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,722	2,692
Fair Value Measurements Recurring \| Money Market Accounts \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,722	2,692
Fair Value Measurements Recurring \| Money Market Accounts \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring \| Money Market Accounts \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring \| United States Treasury
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	999	990
Fair Value Measurements Recurring \| United States Treasury \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| United States Treasury \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	999	990
Fair Value Measurements Recurring \| United States Treasury \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	27,720	28,904
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	27,720	28,904
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	798	790
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	798	790
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 0	$ 0

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Jun. 30, 2019 USD ($)
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0
Fair value assets, transfers between levels, amount	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	13,000
Other-than-temporary impairment losses related to marketable securities	$ 0

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 12,874	$ 12,332
Less: Accumulated depreciation	(6,937)	(5,886)
Fixed assets, net	5,937	6,446
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,687	1,579
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 530	495
Useful life in years	3 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 8,136	8,136
Useful life in years	5 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 234	233
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 802	802
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,485	$ 1,087

Fixed Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 511,000	$ 562,000	$ 1,046,000	$ 1,078,000

Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Reagents	$ 405	$ 314
Prepaid expenses	1,024	706
Prepaid income taxes	609	1,251
Marketable securities interest receivable	196	220
Other receivable	33	70
Total	$ 2,267	$ 2,561

Reporting Segment and Geographical Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2019 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenue	$ 8,424	$ 5,400	$ 13,794	$ 10,053
United States
Segment Reporting Information [Line Items]
Revenue	6,686	3,299	10,300	5,826
Canada
Segment Reporting Information [Line Items]
Revenue	516	1,070	1,054	2,040
Other Countries
Segment Reporting Information [Line Items]
Revenue	$ 1,222	$ 1,031	$ 2,440	$ 2,187

Commitments and Contingencies - Additional Information (Details) - Reagents $ in Millions	Jun. 30, 2019 USD ($)
Commitments And Contingencies [Line Items]
Non-cancelable purchase obligations	$ 5.8
Non-cancelable purchase obligations, payable within next twenty-four months	3.7
Non-cancelable purchase obligations, payable within twelve months	$ 2.1

Leases - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
Leases - Additional Information (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 01, 2019
Leases [Abstract]
Operating leases term of expiration			2023-08
Operating leases, renewal term	3 years		3 years
Operating leases, rent expense	$ 133,000	$ 119,000	$ 266,000	$ 228,000
Long-term ROU assets	2,756,000		2,756,000		$ 3,000,000
Short-term lease liabilities	401,000		401,000		384,000
Long-term lease liabilities	$ 2,385,000		2,385,000		$ 2,600,000
Impact to retained earnings upon adoption ASC 842			$ 0

Leases - Schedule of Operating Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 146	$ 292

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 116	$ 278
Operating cash flows from operating leases	$ 101	$ 201

Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Jun. 30, 2019
Leases [Abstract]
Weighted average remaining lease term - operating leases	6 years 1 month 6 days
Weighted average discount rate - operating leases	6.25%

Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
2019 (remaining 6 months)	$ 281
2020	559
2021	550
2022	558
2023	567
2024	330
Thereafter	532
Total lease payments	3,377
Less imputed interest	(591)
Total	$ 2,786	$ 3,000

Leases - Schedule of Future Minimum Payments for Noncancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 560
2020	559
2021	550
2022	558
2023	567
Thereafter	862
Total minimum lease payments	$ 3,656

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 737	$ 573	$ 1,320	$ 1,118
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	167	151	309	275
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	233	171	411	303
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	186	113	311	221
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 151	$ 138	$ 289	$ 319

Income Taxes - Additional Information (Details)	3 Months Ended		6 Months Ended
Income Taxes - Additional Information (Details)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate	1.00%	11.00%	(2.00%)	18.00%

Loss per Share - Reconciliation of Basic and Diluted Loss Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Weighted-average common shares—outstanding, basic	18,343	17,919	18,286	17,891
Weighted-average common shares—outstanding, diluted	19,021	17,919	18,286	17,891
Net income (loss) per common share, basic	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Net income (loss) per common share, diluted	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227

+ Details

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Loss per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	19	436	387	433
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	358	1,055	1,093	961

Related Party - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Apr. 30, 2017
Related Party Transaction [Line Items]
Ownership percentage	30.00%		30.00%		30.00%
Xilong Scientific
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	11.00%		11.00%
Foundation
Related Party Transaction [Line Items]
Revenue from related parties	$ 8,000	$ 0	$ 16,000	$ 8,000
Due from related parties	2,000		2,000		$ 0
Foundation \| Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties	2,000	0	2,000	0
University
Related Party Transaction [Line Items]
Revenue from related parties	9,000	$ 7,000	22,000	$ 16,000
Due from related parties	$ 18,000		$ 18,000		51,000
FF Gene Biotech \| FJIP
Related Party Transaction [Line Items]
Ownership percentage						19.00%
FF Gene Biotech \| Dr. Han Lin Gao \| FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%		25.00%
Fulgent Pharma
Related Party Transaction [Line Items]
Due from related parties	$ 29,000		$ 29,000		$ 22,000

Equity Method Investments - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2017 CNY (¥)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 CNY (¥)	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Ownership interest to be made in joint venture		30.00%		30.00%		30.00%	30.00%
Royalty earned \| $		$ 8,424,000	$ 5,400,000	$ 13,794,000	$ 10,053,000
Royalty \| License Agreement
Schedule Of Equity Method Investments [Line Items]
Royalty earned \| $			$ 17,000		$ 35,000
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture \| ¥	¥ 60,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	30.00%	30.00%		30.00%		30.00%	30.00%
Contributions remain for joint venture		$ 5,900,000		$ 5,900,000		¥ 40,300,000
FF Gene Biotech \| Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture \| $				$ 3,000,000
Xilong Scientific \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture \| ¥	¥ 102,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	51.00%
FJIP \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture \| ¥	¥ 19,000,000
Contribution period in joint venture	10 years
Previous contribution period in joint venture	5 years
Ownership interest to be made in joint venture	19.00%

Equity Method Investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Apr. 30, 2017
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,084	$ 1,512
Ownership percentage	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,084	$ 1,512
Ownership percentage	30.00%	30.00%	30.00%

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Balance Sheet Data (Details) - FF Gene Biotech - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Current Assets	$ 2,367	$ 1,916
Non-Current Assets	3,892	4,068
Current Liabilities	4,318	2,415
Minority Interest	207
Shareholders' Equity	$ 1,734	$ 3,569

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Statement of Operations Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Schedule Of Equity Method Investments [Line Items]
Equity loss in investee	$ (149)	$ (246)	$ (428)	$ (491)
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Net Sales			1,131	349
Gross Profit			579	(1)
Net Loss			(1,423)	(1,637)
Equity loss in investee			$ (428)	$ (491)

- Definition

This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.

+ References + Details